Circio Holding Past Earnings Performance
Past criteria checks 0/6
Circio Holding's earnings have been declining at an average annual rate of -22.9%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 53.4% per year.
Key information
-22.9%
Earnings growth rate
14.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 53.4% |
| Return on equity | n/a |
| Net Margin | -90,029.3% |
| Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Circio Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -111 | 35 | 50 |
| 30 Sep 23 | 10 | -446 | 42 | 62 |
| 30 Jun 23 | 10 | -449 | 45 | 66 |
| 31 Mar 23 | 10 | -440 | 48 | 59 |
| 31 Dec 22 | 10 | -433 | 53 | 47 |
| 30 Sep 22 | 0 | -107 | 53 | 41 |
| 30 Jun 22 | 0 | -110 | 54 | 43 |
| 31 Mar 22 | 0 | -106 | 54 | 38 |
| 31 Dec 21 | 0 | -98 | 49 | 37 |
| 30 Sep 21 | 0 | -98 | 48 | 73 |
| 30 Jun 21 | 0 | -97 | 46 | 63 |
| 31 Mar 21 | 0 | -105 | 44 | 54 |
| 31 Dec 20 | 1 | -108 | 44 | 45 |
| 30 Sep 20 | 3 | -117 | 43 | 0 |
| 30 Jun 20 | 3 | -120 | 42 | 0 |
| 31 Mar 20 | 3 | -132 | 43 | 0 |
| 31 Dec 19 | 2 | -148 | 45 | 0 |
| 30 Sep 19 | 0 | -153 | 52 | 0 |
| 30 Jun 19 | 0 | -162 | 56 | 0 |
| 31 Mar 19 | 0 | -153 | 59 | 0 |
| 31 Dec 18 | 0 | -147 | 61 | 0 |
| 30 Sep 18 | 0 | -139 | 60 | 0 |
| 30 Jun 18 | 0 | -132 | 60 | 0 |
| 31 Mar 18 | 0 | -129 | 57 | 0 |
| 31 Dec 17 | 0 | -122 | 53 | 0 |
| 30 Sep 17 | 0 | -121 | 53 | 0 |
| 30 Jun 17 | 0 | -119 | 52 | 0 |
| 31 Mar 17 | 0 | -118 | 51 | 0 |
| 31 Dec 16 | 0 | -122 | 54 | 0 |
| 30 Sep 16 | 0 | -134 | 53 | 0 |
| 30 Jun 16 | 0 | -137 | 56 | 0 |
| 31 Mar 16 | 0 | -117 | 48 | 0 |
| 31 Dec 15 | 0 | -92 | 37 | 0 |
| 30 Sep 15 | 0 | -57 | 23 | 0 |
| 30 Jun 15 | 0 | -32 | 11 | 0 |
| 31 Mar 15 | 0 | -22 | 8 | 0 |
| 31 Dec 14 | 0 | -18 | 6 | 0 |
| 30 Sep 14 | -3 | -12 | 2 | 0 |
| 30 Jun 14 | -1 | -10 | 2 | 0 |
| 31 Mar 14 | 0 | -9 | 3 | 0 |
| 31 Dec 13 | 0 | -8 | 3 | 0 |
Quality Earnings: TA50 is currently unprofitable.
Growing Profit Margin: TA50 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TA50 is unprofitable, and losses have increased over the past 5 years at a rate of 22.9% per year.
Accelerating Growth: Unable to compare TA50's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TA50 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: TA50's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.